

Workshop: Learn The Key Features of VantagePoint - Smart Charts Edition Version 11 By Building A Trials Piano Chart

Description and Goals

In this workshop, you will learn how to use many of the key features in Version 11 of VantagePoint - Smart Charts Edition (VP-SCE) to import and clean-up data and then create a Trials Piano Chart visualization.

VantagePoint – Smart Charts Edition (VP-SCE) offers BizInt Smart Charts users powerful features for normalizing and filtering data in multi-database reports. Used in conjunction with the BizInt Smart Charts Reference Rows utility, VantagePoint helps BizInt Smart Charts users create enhanced reports and visualizations from drug pipeline, clinical trials, patents and IP sequence reports. Version 11 of VP-SCE provides a redesigned user interface and new features.

What do I need for this workshop?

For this workshop, you need to have VantagePoint - Smart Charts Edition Version 11.

If you do not have a VP-SCE license you may request a free trial at www.bizint.com/try.

The workshop uses a **training.vpxi** file which was created by searching for Merkel Cell Carcinoma trials in ClinicalTrials.gov and EU Clinical Trials (EudraCT), importing the results into the BizInt Smart Charts Drug Development Suite and then integrating results for each trial in BizInt Smart Charts Reference Rows. In Reference Rows we applied column rules and reviewed the data to select representative values for each trial and then exported to create the training.vpxi file.

The training.vpxi file used in this workshop can be found at: www.bizint.com/vptraining

Phase 1	Phase I/II	Phase II
NC100655655 National Cancer Institute (NCI)	NCT02888759 Bristol-Myers Squibb	NCT00013779 Trans-Tauman Radiarion Oncology Group (TRDG)
NC102890368 Trillium Therapeutics Inc.	NCT01440816 Merck KGAA	NCTODDEG75 Exellust
NC102000257 A22/Vie	NCT02514824 Millennium Pharmaceuticals, Inc.	Notional Cancer Institute (NCI)
NC702071767 Abb/Ke	NCT02542882 Mediamune LLC	2011-001226-27 Glassienithäise
NC103107663 ImaginAb, Inc.	NCT02984522 Tarveda Therapeutics	2014-004725-39 Novatis
NC102821179 National Cancer Institute (NCI)	NCT03226150 Incyte Corporation	2016-000461-22 Bristol-Myers Squibb
NC102212404 Checkpoint Therapeutics, Inc.	NCT02557254 NantCell, Inc.	NCT02155647 Merck REaA
	NCT02241172 Incyte Corporation	NCT02156861 Bristol-Myers Squibb
		NCT02251128 University Hospital, Grenoble
		NCT03665657 NantCwed, Inc.
		NCTO28159682 Arrigen
		NCT03071405 Bristol-Myers Squibb
		NCT028796225 National Cancer Institute (NCI)
		manifester(s)
		Altra-ball Northering
		Marca Control
P-SCE		Mpun Annung Mpunat
iano hart		

► For more info: www.bizint.com/tips

QUESTIONS OR SUGGESTIONS? Please contact us at: Support@bizint.com Intervention Interventint

© 2019 BizInt Solutions, Inc. 08/2019

Import data

Open VantagePoint - Smart Charts Edition (VP-SCE)

1. Select the Import XML (Smart Data Exchange) radio button and click OK. Find the training.vpxi file and click Open.

VP-SCE will import the sample data.

When importing finishes you will see the Summary Sheet which shows the columns from BizInt Smart Charts displayed as fields. Most analysis and clean-up steps start from the Summary Sheet and you will often need to return here while working with a dataset. Many functions are accessible by right-clicking on a field name.

Clean-up sponsor names:

- 2. On the Summary Sheet screen, right-click on the Sponsor field and select List Cleanup.
- 3. Under matching ruleset, select Organization Names (Pharma) and click OK.

The Dual View Cleanup Confirmation panel is displayed. Don't worry if this appears confusing at first. There is a lot here, but it is all designed to make clean-up tasks easier.


For now, focus on the two panels with lists of terms. At the start, the left panel lists terms by record count and the right panel list is in alphabetical order. These default settings are a good place to start.

Both lists show that the matching ruleset you selected has automatically combined two different versions of Bristol-Myers Squibb and selected the shorter version as the preferred term. Once you finish this list cleanup, the new Sponsor (Cleaned) field will only show "Bristol-Myers Squibb". In a larger dataset, you will see more terms combined automatically.

You can also combine terms manually. Drag and drop a synonym onto a preferred term to combine.

- 4. In either panel, drag "Incyte Biosciences International..." onto "Incyte Corporation" to combine these terms.
- 5. Drag "EMD Serono" onto the parent company, "Merck KGaA". Tip: Want to double-check US Merck or German Merck? Rightclick on EMD Serono and choose either Search Google or Search

Wikipedia for a quick check online Your panel should now look like the one above.



6. Click the Accept button to complete the list cleanup. Click No to skip saving as a thesaurus.

With a larger dataset, you may wish to save as a thesaurus to save you time the next time you have to clean-up the same type of information, organization names in this case.

A new field "Sponsor (Cleaned)" is created. Note that Bristol-Meyers Squibb now appears only once in the list. For more information on using List Cleanup, see the Techniques: Using List Cleanup recipe in the Cookbook.

Return to the Summary Sheet

7. Click the First Sheet button (top left, next to the save icon) to return to the Summary Sheet.

Note: The Summary Sheet is where you can navigate between lists. You can right-click on a field name and use Rename Field to rename a field.

Normalize Phase and Status

8. Set Phase as the Data Type for your phase field: Right click on the phase field, and from the "Set Data Type" submenu, select "Custom" and then "Phase".

The Data Type column now shows Phase. This will cause phases to sort in phase order (not alphabetically) in your visualization.

 Normalize phase: Right-click on the phase field and choose Thesaurus. Under Thesaurus, select DrugDevelopmentPhases_ Arabic.


Note: if you don't see this file, click on the folder icon and go up one level to VantagePoint - SCE and select the Thesaurus folder.


10. Click OK to apply the thesaurus.


You will now have a new cleaned up field, "Phase (1)" with three phases - Phase 2, Phase 1/2, and Phase 1.


11. Normalize status: Return to the Summary Sheet. Right-click on the Overall Status field and choose Thesaurus. Under Thesaurus, select the "TrialStatus" file and click OK.


You will now have one more cleaned up field, "OverallStatus (1)" with four trial phases as shown at right.











Build the Piano Chart

Having cleaned up sponsors, phases and trial status, you are ready to build your visualization.

- 12. Build the Piano Chart: Go to the Report tab and click on Piano Chart.
- 13. In Step 1, choose the Common Trial ID field for the Box Labels and choose your cleaned-up Phase (1) field for the Phase.
- 14. In Step 2, choose the cleaned Sponsor (Cleaned) field to add to the Boxes and the normalized Overall Status (1) field as the Field to Color Code the Boxes. Select the check box to add hyperlinks to trial records.

Note: record links can be followed in PowerPoint in the Slide Show view.

- 15. In Step 3, enter a title like "MCC Trials" for your chart. In Step 4, select the radio button for PowerPoint.
- 16. Check that your panel looks like the one at right, and click "Create Piano Chart".

Some intermediate windows will appear and then VP-SCE will create a new document in PowerPoint and draw the piano chart.


- 17. Switch to PowerPoint to see the Piano Chart. Your piano chart should look similar to the one below.
- 18. Save the file in PowerPoint.

Note: You can edit the chart in PowerPoint and follow links to the trial records in the PowerPoint show.

- 19. Save your work in VP-SCE: Go to the Home tab and select Save to save as a .vpt file.
- 20. Congratulations you are done! Send the PowerPoint file and VP-SCE .vpt file to us at support@bizint.com

Report	Editors	View	Help		
		\bigcirc			
Bubble Ga	ntt Cluster	World	Event	Piano	Duration Bu
Chart Ch	art Map	Мар	Timeline	Chart	Timeline
et			Sm	hart Cha	arts Reports

	Chart					×
Piano	Chart					
Select a Temp	late:					
Select a Temp	plate					~
Step 1: Select Select a Field						
Common Tria	IID					~
Select a Field	for the Phase	2:				
Phase (1)						~
Sponsor (Clea	aned)					~
Sponsor (Clea	aned)					~
Choose a Field	to Color Co	ode the Box	es:			*
	to Color Co	ode the Box	es:			*
Choose a Field Overall Status	to Color Co s (1) links to drug		es:			*
Choose a Field Overall Status Add hyper Step 3: Set Cha	to Color Co s (1) links to drug		es:			~
Choose a Field Overall Status Add hyper Step 3: Set Cha Chart Title:	to Color Co s (1) links to drug art Title: MCC Trials		es:			* *
Choose a Field Overall Status Add hyper Step 3: Set Cha Chart Title: Step 4: Create	d to Color Co s (1) links to drug art Title: MCC Trials Piano Chart	records				~
Choose a Field Overall Statu: Add hyper Step 3: Set Chi Chart Title: Step 4: Create Choose the ex	d to Color Co s (1) links to drug art Title: MCC Trials Piano Chart port format	records		łowerPoin	it 🔍 Ex	~ cel
Choose a Field Overall Status Add hyper Step 3: Set Cha Chart Title: Step 4: Create	d to Color Co s (1) links to drug art Title: MCC Trials Piano Chart port format	records		YowerPoin	it 🔍 Ex	×
Choose a Field Overall Statu: Add hyper Step 3: Set Chi Chart Title: Step 4: Create Choose the ex	d to Color Co s (1) links to drug art Title: MCC Trials Piano Chart port format	records		PowerPoin	it C Ex	×



Phase I	Phase I/II	Phase II
CT00655655 ational Cancer Institute (NCI)	NCT02488759 Bristol-Myers Squibb	NCT01013779 Trans-Tasman Radiation Oncology Group (TROG)
CT02890368 illium Therapeutics Inc.	NCT01440816 Merck KGaA	NCT02036476 Exelixis
CT03000257 bbVie	NCT02514824 Millennium Pharmaceuticals, Inc.	NCT02267603 National Cancer Institute (NCI)
CT03071757 bbVie	NCT02643303 Medimmune LLC	2011-003226-27 GlaxoSmithKline
CT03107663 JaginAb, Inc.	NCT02936323 Tarveda Therapeutics	2014-004735-39 Novartis
CT02831179 ational Cancer Institute (NCI)	NCT03126110 Incyte Corporation	2016-000461-23 Bristol-Myers Squibb
CT03212404 neckpoint Therapeutics, Inc.	NCT03167164 NantCell, Inc.	NCT02155647 Merck KGaA
	NCT03241173 Incyte Corporation	NCT02196961 Bristol-Myers Squibb
		NCT02351128 University Hospital, Grenoble
		NCT02465957 NantKwest, Inc.
		NCT02819843 Amgen
		NCT03071406 Bristol-Myers Squibb
		NCT02978625 National Cancer Institute (NCI)
		Overall Status (1)
		Active, Not Recruiting Ongoing
		Open, Recruiting
SCE		Planned